ECSP10010471A - Agonistas nicotínicos alfa 7 y antipsicóticos - Google Patents

Agonistas nicotínicos alfa 7 y antipsicóticos

Info

Publication number
ECSP10010471A
ECSP10010471A EC2010010471A ECSP10010471A ECSP10010471A EC SP10010471 A ECSP10010471 A EC SP10010471A EC 2010010471 A EC2010010471 A EC 2010010471A EC SP10010471 A ECSP10010471 A EC SP10010471A EC SP10010471 A ECSP10010471 A EC SP10010471A
Authority
EC
Ecuador
Prior art keywords
antipsychotic
alfa
nicotine agonists
nicotine
agonists
Prior art date
Application number
EC2010010471A
Other languages
English (en)
Spanish (es)
Inventor
Merouane Bencherif
Gregory J Gatto
Kristen G Jordan
Sharon R Letchworth
Terry Hauser
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of ECSP10010471A publication Critical patent/ECSP10010471A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
EC2010010471A 2008-02-13 2010-09-09 Agonistas nicotínicos alfa 7 y antipsicóticos ECSP10010471A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13

Publications (1)

Publication Number Publication Date
ECSP10010471A true ECSP10010471A (es) 2010-10-30

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010471A ECSP10010471A (es) 2008-02-13 2010-09-09 Agonistas nicotínicos alfa 7 y antipsicóticos

Country Status (25)

Country Link
US (1) US20110059947A1 (https=)
EP (2) EP2254598B1 (https=)
JP (1) JP2011511845A (https=)
KR (1) KR20100113163A (https=)
CN (2) CN103143023A (https=)
AU (1) AU2009214625A1 (https=)
BR (1) BRPI0907570A2 (https=)
CA (1) CA2715268A1 (https=)
CO (1) CO6290706A2 (https=)
CY (1) CY1114492T1 (https=)
DK (1) DK2254598T3 (https=)
EC (1) ECSP10010471A (https=)
ES (1) ES2430622T3 (https=)
HR (1) HRP20130749T1 (https=)
IL (1) IL207389A0 (https=)
MX (1) MX2010008875A (https=)
NZ (1) NZ587312A (https=)
PL (1) PL2254598T3 (https=)
PT (1) PT2254598E (https=)
RS (1) RS52941B (https=)
RU (1) RU2481123C2 (https=)
SG (1) SG188144A1 (https=)
SI (1) SI2254598T1 (https=)
WO (1) WO2009102962A2 (https=)
ZA (1) ZA201005999B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN103180321A (zh) 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
TW201242600A (en) * 2011-01-18 2012-11-01 Targacept Inc Treatment of cognitive dysfunction in schizophrenia
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
WO2014054635A1 (ja) * 2012-10-02 2014-04-10 大日本住友製薬株式会社 イミダゾール誘導体
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
EP1083889B1 (en) 1998-06-01 2003-12-10 Ortho-McNeil Pharmaceutical, Inc. Tetrahydronaphtalene compounds and their use for the treatment of neurodegenerative diseases
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
CZ20021880A3 (cs) * 1999-12-10 2002-08-14 Wyeth Farmaceutický prostředek
CZ294251B6 (cs) * 2000-06-27 2004-11-10 Laboratorios S. A. L. V. A. T., S. A. Karbamáty a jejich použití pro výrobu farmaceutického prostředku
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
EP1311505A2 (en) 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
AU2003217275A1 (en) * 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
EA200500738A1 (ru) * 2002-12-06 2005-12-29 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи КРИСТАЛЛИЧЕСКИЕ ФУМАРАТНЫЕ СОЛИ 1-АЗАБИЦИКЛО [2.2.2]ОКТЗАМЕЩЕННОГО ФУРО [2,3-c] ПИРИДИНИЛКАРБОКСАМИДА И ИХ КОМПОЗИЦИИ И ПОЛУЧЕНИЕ
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Also Published As

Publication number Publication date
MX2010008875A (es) 2010-08-31
RU2481123C2 (ru) 2013-05-10
PL2254598T3 (pl) 2013-12-31
WO2009102962A2 (en) 2009-08-20
RS52941B (sr) 2014-02-28
RU2010137787A (ru) 2012-03-20
EP2254598A2 (en) 2010-12-01
ES2430622T3 (es) 2013-11-21
CA2715268A1 (en) 2009-08-20
HRP20130749T1 (en) 2013-10-11
CO6290706A2 (es) 2011-06-20
SG188144A1 (en) 2013-03-28
BRPI0907570A2 (pt) 2019-09-24
JP2011511845A (ja) 2011-04-14
IL207389A0 (en) 2010-12-30
CN103143023A (zh) 2013-06-12
US20110059947A1 (en) 2011-03-10
WO2009102962A3 (en) 2009-10-08
HK1147954A1 (en) 2011-08-26
ZA201005999B (en) 2011-05-25
EP2633868A1 (en) 2013-09-04
CY1114492T1 (el) 2016-10-05
NZ587312A (en) 2011-12-22
CN101977628A (zh) 2011-02-16
AU2009214625A1 (en) 2009-08-20
DK2254598T3 (da) 2013-07-29
PT2254598E (pt) 2013-10-16
KR20100113163A (ko) 2010-10-20
SI2254598T1 (sl) 2013-10-30
EP2254598B1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
ECSP10010471A (es) Agonistas nicotínicos alfa 7 y antipsicóticos
CO6210786A2 (es) Implemento de cuidado oral que alberga un agente de cuidado oral
CL2010001428A1 (es) Compuestos derivados de amidas y tioamidas heteroaromaticas; agente que contiene al menos uno de dichos compuestos; procedimiento para combatir parasitos; y uso de dichos compuestos.
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
UY33397A (es) Forma sólida de un naftaleno carboxamida
ECSP11010986A (es) Combinación de una insulina y un agonista de glp-1
MY156511A (en) Compositions and devices
PH12013501312A1 (en) Fluid compositions comprising a structuring agent
GT200800123A (es) Compuestos mimeticos de lisina modificados
EP2176769A4 (en) DELEGATE INSTANT MESSAGING MEETINGS
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
DOP2010000225A (es) Arilpirrolinas insecticidas
HN2008000278A (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion terapeutica
MX2012008717A (es) Composiciones para el cuidado oral.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2007001457A1 (es) Preparacion oral que comprende pioglitazona o una sal de la misma y un cloruro de metal alcalino, util como hipoglicemiante.
AR083417A1 (es) Composiciones farmaceuticas que contienen un dgat1 inhibidor
AR059444A1 (es) Composiciones ramnolipidicas y metodos de uso relacionados
CL2012002382A1 (es) Combinaciones fungicidas que consisten de tebuconazol, axistrobina y fludioxonil, y uno o más auxiliares de formulación habituales (div. sol. 1791-07).
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
BRPI0915373A2 (pt) composições de agente de branqueamento fluorescente
CR20150275A (es) Composición de difenidol de liberación prolongada
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.